# A Phase 1/2 Trial of ADI-270 in ccRCC

Source: https://onco.cc/trials/nct06480565/  
OnCo record `nct06480565` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ADI-270, Fludarabine, Cyclophosphamide in renal cell carcinoma, run by Adicet Therapeutics, active and no longer recruiting.

## Summary

A Phase 1/2 Trial of ADI-270 in ccRCC is a phase 1/2 interventional study registered as NCT06480565 by Adicet Therapeutics, with 60 participants planned, started 2024-12-12 and due to reach its primary completion in 2026-12. Interventions recorded: ADI-270, Fludarabine, Cyclophosphamide. Conditions listed: Clear Cell Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06480565
- Phase: 1/2
- Setting: A Phase 1/2 Trial of ADI-270 (Engineered γδ Chimeric Receptor [CAR] Vδ1 T Cells Targeting CD70) in Adults With Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma (ccRCC)
- Sponsor: Adicet Therapeutics
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06480565: https://clinicaltrials.gov/study/NCT06480565

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [ADI-270](https://onco.cc/drugs/adi-270/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct06480565.json